Brookfield Asset Management Ltd. is a private equity firm specializing in acquisitions and growth capital investments. The firm primarily provides its services to institutional clients, high net worth individuals, financial institutions, public and private pension plans, sovereign wealth funds, endowments, and foundations. The firm manages separate client-focused public and private fund portfolios, listed partnerships, separate accounts, and co-investments. The firm invests in real assets, including real estate, infrastructure, renewable power, private equity, and credit. The firm employs fundamental and operational analysis to make its investments. The firm uses both in-house and external research to complement its investment process. Brookfield Asset Management Ltd. was founded in 2022 and is based in New York. Brookfield Asset Management Ltd. operates as a subsidiary of Brookfield Corporation.…
Brookfield Real Assets Income Fund Inc. Announces Service Provider and Portfolio Management Changes
Brookfield Asset Management (NYSE: BAM) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Asset Management industry, part of the Financial Services sector, and reports about 5,800 employees.
The shares were at 48.94 USD on 20 November 2026, down 0.5% over 52 weeks. Its 52-week range is 42.20 USD to 55.97 USD: the price is 12.6% below the high and 16.0% above the low.
At a market capitalisation of 78.20B USD, it trades at 16.6 times trailing earnings and 22.7 times forward earnings. The median trailing P/E of its 18 largest Asset Management peers is 12.9, a premium of 29% for BAM. It pays a dividend yielding 4.00% (it pays out 66% of its earnings), against a median of 1.69% among the dividend payers in that peer group.
Brookfield Asset Management reports return on equity of 30.6%, an operating margin of 66.6% and revenue up 71.6% year over year.
Its debt exceeds its cash by 5.55B USD, a debt-to-equity ratio of 0.45. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 57.34 USD is 17.2% above the current price. The next earnings report is expected on 3 February 2027.